NapabucasinSTAT3 inhibitor CAS# 83280-65-3 |
2D Structure
- 5-Azacytidine
Catalog No.:BCC1130
CAS No.:320-67-2
- Zebularine
Catalog No.:BCC1136
CAS No.:3690-10-6
- RG 108
Catalog No.:BCC1134
CAS No.:48208-26-0
- Nanaomycin A
Catalog No.:BCC3611
CAS No.:52934-83-5
- SGI-110
Catalog No.:BCC2221
CAS No.:929901-49-5
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 83280-65-3 | SDF | Download SDF |
PubChem ID | 10331844 | Appearance | Powder |
Formula | C14H8O4 | M.Wt | 240.21 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : 7.14 mg/mL (29.72 mM; Need ultrasonic and warming) H2O : < 0.1 mg/mL (insoluble) | ||
Chemical Name | 2-acetylbenzo[f][1]benzofuran-4,9-dione | ||
SMILES | CC(=O)C1=CC2=C(O1)C(=O)C3=CC=CC=C3C2=O | ||
Standard InChIKey | DPHUWDIXHNQOSY-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C14H8O4/c1-7(15)11-6-10-12(16)8-4-2-3-5-9(8)13(17)14(10)18-11/h2-6H,1H3 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | STAT3 inhibitor. Blocks spherogenesis of cancer stem cells (CSC), but not hematopoietic stem cells. Inhibits PaCa-2 xenograft tumor growth in mice, even after cessation of treatment, and decreases population of CSCs in PaCa-2 tumors from treated mice. Also blocks spleen and liver metastases of colon cancer cells in a mouse model. |
Napabucasin Dilution Calculator
Napabucasin Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 4.163 mL | 20.8151 mL | 41.6302 mL | 83.2605 mL | 104.0756 mL |
5 mM | 0.8326 mL | 4.163 mL | 8.326 mL | 16.6521 mL | 20.8151 mL |
10 mM | 0.4163 mL | 2.0815 mL | 4.163 mL | 8.326 mL | 10.4076 mL |
50 mM | 0.0833 mL | 0.4163 mL | 0.8326 mL | 1.6652 mL | 2.0815 mL |
100 mM | 0.0416 mL | 0.2082 mL | 0.4163 mL | 0.8326 mL | 1.0408 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Target: Signal transducer and activator of transcription 3 (Stat3)
IC50: 0.395 μM (Bulk cells), 0.142 μM (Cancer stem cells)
Napabucasin, also named (BBI608), is an orally available small molecule by the ability to inhibit gene transcription of STAT3 and cancer stemness properties and suppresses spherogenesis or kills stemnesshigh cancer cells isolated from several kinds of cancer types [1]. Stat3 is critically important for maintaining cancer stemness.
In vitro: Napabucasin (1 μmol/L) not only decreased cell viability, migration, colony formation, and survival with cell cycle arrest, and increased cell apoptosis and sensitivity to docetaxel, but also obviously blocked PrCSCs sphere formation and killed them in vitro [1]. Napabucasin (1, and 2 μmol/L) decreased the expressions of stemness markers such as Nanog, Klf4, survivin, C-myc, and β-catenin [1].
In vivo: Napabucasin (40 mg/kg, i.p. injection) inhibited tumor growth on prostate cancer (PCa) mouse xenograft models, the PC-3 cells or 22RV1 cells were inoculated into nude mice. In addition, Napabucasin suppressed the self-renewal of stemness-high prostate cancer (PCa) cells in vivo [1]. Moreover, Napabucasin (20 mg/kg, i.p. injection) effectively blocked cancer relapse and metastasis in xenografted human cancers including PaCa-2 human pancreatic cancer and HT29 human colon cancer [2].
References:
1. Zhang Y, Jin Z, Zhou H, Ou X, Xu Y, Li H, et al. Suppression of prostate cancer progression by cancer cell stemness inhibitor napabucasin. Cancer Med. 2016;5(6):1251-8.
2. Li Y, Rogoff HA, Keates S, Gao Y, Murikipudi S, Mikule K, et al. Suppression of cancer relapse and metastasis by inhibiting cancer stemness. Proc Natl Acad Sci U S A. 2015;112(6):1839-44.
- Lauryl-LF 11
Catalog No.:BCC6175
CAS No.:832729-14-3
- LF 11
Catalog No.:BCC6174
CAS No.:832729-13-2
- APD668
Catalog No.:BCC5389
CAS No.:832714-46-2
- Angelol H
Catalog No.:BCN8047
CAS No.:83247-73-8
- Dehydrocavidine
Catalog No.:BCN2549
CAS No.:83218-34-2
- 1beta-Hydroxy-beta-eudesmol
Catalog No.:BCN7097
CAS No.:83217-89-4
- ISX 9
Catalog No.:BCC6181
CAS No.:832115-62-5
- Astragaloside A
Catalog No.:BCC6494
CAS No.:83207-58-3
- 2',4',6'-Trimethoxyacetophenone
Catalog No.:BCN4847
CAS No.:832-58-6
- Angelol G
Catalog No.:BCN7963
CAS No.:83199-38-6
- 8alpha-Tigloyloxyhirsutinolide 13-O-acetate
Catalog No.:BCN7108
CAS No.:83182-58-5
- Kaempferol 3-O-rhamninoside
Catalog No.:BCN6845
CAS No.:83170-31-4
- Menisporphine
Catalog No.:BCN7902
CAS No.:83287-02-9
- 7-Hydroxycoumarin-6-carboxylic acid
Catalog No.:BCN4375
CAS No.:833-52-3
- Bryostatin 1
Catalog No.:BCC7343
CAS No.:83314-01-6
- 8(17),13-Labdadien-15,16-olide
Catalog No.:BCN4374
CAS No.:83324-51-0
- (-)-Lariciresinol
Catalog No.:BCN3418
CAS No.:83327-19-9
- Dynorphin B
Catalog No.:BCC5987
CAS No.:83335-41-5
- 10-O-Caffeoyl-6-epiferetoside
Catalog No.:BCN4822
CAS No.:83348-22-5
- 25(R)-Hydroxyprotopanaxadiol
Catalog No.:BCN2493
CAS No.:83349-37-5
- D609
Catalog No.:BCC1509
CAS No.:83373-60-8
- Prenyl caffeate
Catalog No.:BCC8351
CAS No.:100884-13-7
- PL 017
Catalog No.:BCC5864
CAS No.:83397-56-2
- Phenformin HCl
Catalog No.:BCC4362
CAS No.:834-28-6
Suppression of prostate cancer progression by cancer cell stemness inhibitor napabucasin.[Pubmed:26899963]
Cancer Med. 2016 Jun;5(6):1251-8.
A small population of cells with stem cell-like properties in prostate cancer (PCa), called prostate cancer stem cells (PrCSCs) or prostate stemness-high cancer cells, displays highly tumorigenic and metastatic features and may be responsible for the therapy resistance. A small molecule, Napabucasin (BBI608), recently have been identified with suppression of stemness-high cancer cells in a variety of cancers. However, the effects of Napabucasin on PCa cells as well as PrCSCs isolated from PCa cells have not yet been defined. The effect of Napabucasin on PCa cells in cell proliferation, colony formation, and cell migration in vitro were measured by MTS, colony formation assay, and Transwell, respectively. Flow cytometry was employed to evaluate cell cycle and cell apoptosis, and the effect on tumorigenesis in vivo was examined by tumor growth assays. Furthermore, the role of Napabucasin on self-renewal and survival of PrCSCs was evaluated by their ability to grow spheres and cell viability assay, respectively. Western Blot and qRT-PCR were used to determine the effect of Napabucasin on the expressions of stemness markers. Decrease in cell viability, colony formation, migration, and survival with cell cycle arrest, higher sensitivity to docetaxel in vitro, and repressed tumorigenesis in vivo was observed upon Napabucasin treatment. More importantly, Napabucasin can obviously inhibit spherogenesis and even kill PrCSCs in vitro. Downregulation of stemness markers was observed after PrCSCs were treated with Napabucasin. This study demonstrates that Napabucasin may be a novel approach in the treatment of advanced PCa, specifically for castration-resistant prostate cancer (CRPC).
Suppression of cancer relapse and metastasis by inhibiting cancer stemness.[Pubmed:25605917]
Proc Natl Acad Sci U S A. 2015 Feb 10;112(6):1839-44.
Partial or even complete cancer regression can be achieved in some patients with current cancer treatments. However, such initial responses are almost always followed by relapse, with the recurrent cancer being resistant to further treatments. The discovery of therapeutic approaches that counteract relapse is, therefore, essential for advancing cancer medicine. Cancer cells are extremely heterogeneous, even in each individual patient, in terms of their malignant potential, drug sensitivity, and their potential to metastasize and cause relapse. Indeed, hypermalignant cancer cells, termed cancer stem cells or stemness-high cancer cells, that are highly tumorigenic and metastatic have been isolated from cancer patients with a variety of tumor types. Moreover, such stemness-high cancer cells are resistant to conventional chemotherapy and radiation. Here we show that BBI608, a small molecule identified by its ability to inhibit gene transcription driven by Stat3 and cancer stemness properties, can inhibit stemness gene expression and block spherogenesis of or kill stemness-high cancer cells isolated from a variety of cancer types. Moreover, cancer relapse and metastasis were effectively blocked by BBI608 in mice. These data demonstrate targeting cancer stemness as a novel approach to develop the next generation of cancer therapeutics to suppress cancer relapse and metastasis.